InvestorsHub Logo
Followers 2431
Posts 91292
Boards Moderated 7
Alias Born 09/12/2003

Re: None

Saturday, 07/16/2022 4:18:35 PM

Saturday, July 16, 2022 4:18:35 PM

Post# of 6627
Chan Vision 10 years ago is to developed real-estate in the USA. Within last few years he focus and move all his asset into Alset Ehome. Therefore, imho I don't think his plan is allow DSS buyout, but I won't eliminate from consideration the buyout from ProPhase.

In the past I normally do DD and laying it all out in full details for everyone to views, but now I don't spoon-feed no more. However, I will shine some light for the people willing... to dig deep!

A few day ago DSS issue a new amendments presence Impact spin-off IPO & dividend attributed to each share outstanding.

Who's IMPACT and PROPHASE? As you will understand the relationship between Impact and ProPhase along with its scientific research partner Global Research and Discovery Group Sciences (GRDG are exceedingly enormous.

What's Equivir?

Impact BioMedical’s Proprietary Equivir Compound.

The License Agreement with ProPhase obtained exclusive rights worldwide to develop and commercialize Equivir.
Impact received its first Equivir patent (US 10,383,842), which focused on influenza, from the U.S. Patent and Trademark Office on August 20, 2019. Then on June 15, 2021, the USPTO granted a second patent, (Patent # 11,033,528) this time focused on both Ebola and the rhinovirus.

When I read people leaking garbage don't see DSS as a positive here cause they are clueless, lack of knowledge, don't even know ProPhase Labs, Inc. (PRPH) Profit pay dividend and stock trade on Nasdaq $13.98 per share.